Clozapine-Induced Mitochondria Alterations and Inflammation in Brain and Insulin-Responsive Cells

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Contreras Shannon, Vernica ^a   Heart, Dylan L ^a   Paredes, R Madelaine ^b   Navaira, Erica ^b   Catano, Gabriel ^c   Maffi, Shivani Kaushal ^c,d   Walss Bass, Consuelo ^b  

^a ST MARY'S UNIVERSITY   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d Regional Academic Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CLOZAPINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INSULIN; INTERLEUKIN 12P70; INTERLEUKIN 6;

ADIPOCYTE; ANIMAL CELL; ARTICLE; BIOLUMINESCENCE; CELL LYSATE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; INFLAMMATION; LIVER CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; MOUSE; MYOBLAST; NEUROBLASTOMA CELL; NONHUMAN; OBESITY; SUPERNATANT;

3T3-L1 CELLS; ADENOSINE TRIPHOSPHATE; ADIPOCYTES; ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CELL LINE; CLOZAPINE; CYTOKINES; HEPATOCYTES; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; METABOLIC SYNDROME X; MICE; MITOCHONDRIA; MYOBLASTS; NEUROBLASTOMA;

EID: 84875147705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059012     Document Type: Article

References (54)

1. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, et al. (2005) Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 66: 183-194; quiz 147, 273-184.
2. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, et al. (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334-1349.
3. Newcomer JW, (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68 (Suppl 4): 8-13.
4. Newcomer JW, (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68 (Suppl 1): 20-27.
5. Ervin RB, (2009) Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report pp. 1-7.
6. Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO, (2007) The medical cost of cardiometabolic risk factor clusters in the United States. Obesity (Silver Spring) 15: 3150-3158.
7. Wille E, Scholze J, Alegria E, Ferri C, Langham S, et al. (2011) Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ 12: 205-218.
8. Haupt DW, (2006) Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16 (Suppl 3): S149-155.
9. Ruaño G ZS, Goethe JW, editor (2006) Drug-induced metabolic syndrome (DIMS) in psychiatry: a diagnostic need uniquely suited to pharmacogenomics. Washington, DC: AACC Press. 277-282 p.
10. Baig MR, Navaira E, Escamilla MA, Raventos H, Walss-Bass C, (2010) Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations. J Psychiatr Pract 16: 325-333.
11. Walss-Bass C, Weintraub ST, Hatch J, Mintz J, Chaudhuri AR, (2008) Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol 11: 1097-1104.
12. Ji B, La Y, Gao L, Zhu H, Tian N, et al. (2009) A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J Proteome Res 8: 3633-3641.
13. Streck EL, Rezin GT, Barbosa LM, Assis LC, Grandi E, et al. (2007) Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn Schmiedebergs Arch Pharmacol 376: 127-133.
14. Casademont J, Garrabou G, Miro O, Lopez S, Pons A, et al. (2007) Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J Clin Psychopharmacol 27: 284-288.
15. Pillai A, Parikh V, Terry AV Jr, Mahadik SP, (2007) Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 41: 372-386.
16. Polydoro M, Schroder N, Lima MN, Caldana F, Laranja DC, et al. (2004) Haloperidol- and clozapine-induced oxidative stress in the rat brain. Pharmacol Biochem Behav 78: 751-756.
17. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, et al. (2004) Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 372: 157-160.
18. Miljevic C, Nikolic M, Nikolic-Kokic A, Jones DR, Niketic V, et al. (2010) Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 34: 303-307.
19. Heiser P, Sommer O, Schmidt AJ, Clement HW, Hoinkes A, et al. (2010) Effects of antipsychotics and vitamin C on the formation of reactive oxygen species. J Psychopharmacol 24: 1499-1504.
20. Himmerich H, Schonherr J, Fulda S, Sheldrick AJ, Bauer K, et al. (2011) Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 45: 1358-1365.
21. Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, et al. (2009) Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 34: 118-128.
22. Pollmacher T, Haack M, Schuld A, Kraus T, Hinze-Selch D, (2000) Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 34: 369-382.
23. Tschopp J, (2011) Mitochondria: Sovereign of inflammation? Eur J Immunol 41: 1196-1202.
24. Salminen A, Ojala J, Kaarniranta K, Kauppinen A, (2012) Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci 69: 2999-3013.
25. Hulsmans M, Holvoet P, (2010) The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med 14: 70-78.
26. Schrauwen P, Schrauwen-Hinderling V, Hoeks J, Hesselink MK, (2010) Mitochondrial dysfunction and lipotoxicity. Biochim Biophys Acta 1801: 266-271.
27. Martinez JA, (2006) Mitochondrial oxidative stress and inflammation: an slalom to obesity and insulin resistance. J Physiol Biochem 62: 303-306.
28. Olefsky JM, Glass CK, (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219-246.
29. Lowell BB, Shulman GI, (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307: 384-387.
30. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, et al. (2005) Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54: 8-14.
31. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI, (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664-671.
32. Kelley DE, He J, Menshikova EV, Ritov VB, (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51: 2944-2950.
33. Galloway CA, Yoon Y, (2012) Mitochondrial Morphology in Metabolic Diseases. Antioxid Redox Signal.
34. Kaneto H, Katakami N, Kawamori D, Miyatsuka T, Sakamoto K, et al. (2007) Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 9: 355-366.
35. Victor VM, Rocha M, Herance R, Hernandez-Mijares A, (2011) Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des 17: 3947-3958.
36. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, et al. (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208: 519-533.
37. Iborra M, Moret I, Rausell F, Bastida G, Aguas M, et al. (2011) Role of oxidative stress and antioxidant enzymes in Crohn's disease. Biochem Soc Trans 39: 1102-1106.
38. Sell H, Habich C, Eckel J, (2012) Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 8: 709-716.
39. Kalupahana NS, Moustaid-Moussa N, Claycombe KJ, (2012) Immunity as a link between obesity and insulin resistance. Mol Aspects Med 33: 26-34.
40. Jheng HF, Tsai PJ, Guo SM, Kuo LH, Chang CS, et al. (2012) Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol Cell Biol 32: 309-319.
41. Collins TJ, Berridge MJ, Lipp P, Bootman MD, (2002) Mitochondria are morphologically and functionally heterogeneous within cells. EMBO J 21: 1616-1627.
42. Collins TJ, Bootman MD, (2003) Mitochondria are morphologically heterogeneous within cells. J Exp Biol 206: 1993-2000.
43. Okamoto K, Kondo-Okamoto N, (2012) Mitochondria and autophagy: critical interplay between the two homeostats. Biochim Biophys Acta 1820: 595-600.
44. DiMauro S, Tanji K, Bonilla E, Pallotti F, Schon EA, (2002) Mitochondrial abnormalities in muscle and other aging cells: classification, causes, and effects. Muscle Nerve 26: 597-607.
45. Lin DT, Wu J, Holstein D, Upadhyay G, Rourk W, et al. (2007) Ca2+ signaling, mitochondria and sensitivity to oxidative stress in aging astrocytes. Neurobiol Aging 28: 99-111.
46. Ulivieri C, (2010) Cell death: insights into the ultrastructure of mitochondria. Tissue Cell 42: 339-347.
47. Fehsel K, Loeffler S, Krieger K, Henning U, Agelink M, et al. (2005) Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol 25: 419-426.
48. Jou MJ, (2008) Pathophysiological and pharmacological implications of mitochondria-targeted reactive oxygen species generation in astrocytes. Adv Drug Deliv Rev 60: 1512-1526.
49. Dikov D, Aulbach A, Muster B, Drose S, Jendrach M, et al. (2010) Do UCP2 and mild uncoupling improve longevity? Exp Gerontol 45: 586-595.
50. Lim L, Jackson-Lewis V, Wong LC, Shui GH, Goh AX, et al. (2012) Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease. Cell Death Differ 19: 416-427.
51. Lepping P, Delieu J, Mellor R, Williams JH, Hudson PR, et al. (2011) Antipsychotic medication and oxidative cell stress: a systematic review. J Clin Psychiatry 72: 273-285.
52. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116: 115-124.
53. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, Esquivel-Soto J, Morales-Gonzalez A, et al. (2011) Inflammation, oxidative stress, and obesity. Int J Mol Sci 12: 3117-3132.
54. Martinez HG, Quinones MP, Jimenez F, Estrada CA, Clark K, et al. (2011) Critical role of chemokine (C-C motif) receptor 2 (CCR2) in the KKAy + Apoe-/- mouse model of the metabolic syndrome. Diabetologia 54: 2660-2668.